Skip to content
PeptideAI
Approved druglongevity

Lutetium Lu-177 Vipivotide Tetraxetan

A radioactive PSMA-seeking ligand that homes to prostate cancer cells anywhere in the body and irradiates them from the inside — now standard of care in advanced castration-resistant prostate cancer.

Also known as Pluvicto, 177Lu-PSMA-617, lutetium vipivotide, PSMA radioligand therapy, RLT, Pluvicto, PSMA-617, AAA617

Approved drug — Licensed by a major regulator for human use, with phase-3 trial data behind it.

VISION, an 831-patient phase 3 trial in heavily pretreated metastatic castration-resistant prostate cancer, extended median overall survival from 11.3 to 15.3 months and delayed radiographic progression. PSMAfore then showed a 59 percent reduction in the risk of radiographic progression or death in taxane-naive patients after an androgen receptor inhibitor, which drove the March 2025 FDA label expansion to pre-chemotherapy use.

How it works

Prostate-specific membrane antigen is a transmembrane glutamate carboxypeptidase that is expressed at low levels in normal prostate and massively upregulated — often 100 to 1000 fold — in metastatic prostate cancer. PSMA-617 carries a urea-based inhibitor motif that locks into the enzyme's active site, plus a linker tuned for tumour retention and fast renal clearance of unbound drug. The bound complex is internalised and trafficked to endosomes, keeping lutetium-177 inside the cancer cell for days while it emits short-range beta particles that break tumour DNA. Off-target uptake in salivary glands, lacrimal glands, kidneys and small bowel reflects genuine physiological PSMA expression at those sites, which is exactly why dry mouth is the signature side effect.

Targets: Prostate-specific membrane antigen (PSMA / FOLH1), Tumour cell DNA (radiation-induced double-strand breaks)

Dosing

ProtocolDoseFrequencyRoute
Standard VISION regimenGiven as a slow IV injection or short infusion, with hydration before and after.—once every 6 weeks for up to 6 dosesintravenous
  • · 7.4 GBq (200 mCi) per cycle, maximum six cycles. Androgen deprivation and any bone-protective agent continue alongside it. Patients are told to hydrate hard and void frequently for the first 24 hours to clear unbound tracer from the bladder.

Titration

Activity may be reduced to 5.5 GBq or cycles delayed by up to 4 weeks for grade 3 or higher haematologic toxicity, dry mouth or renal decline.

Cycling

Six cycles is the licensed ceiling. Treatment is stopped early for progression or unacceptable marrow toxicity; there is no maintenance phase.

Work out your exact syringe units →

Pharmacology

Half-life
The effective terminal half-life in blood is roughly 40 to 45 hours, sitting on top of the 6.65-day physical half-life of lutetium-177.
Onset
PSA declines are often visible after the first or second cycle, within 6 to 12 weeks; radiographic changes lag behind that.
Routes
intravenous
Molecule
Radiolabelled PSMA-targeting peptidomimetic — a glutamate-urea-lysine binding motif on a DOTA chelator carrying lutetium-177, not a true amino acid chain

Handling

Diluent
Not applicable — supplied as a ready-to-inject radioactive solution in a shielded single-dose vial
Lyophilised
Not applicable — never supplied as a powder.
Reconstituted
Kept below 30 degrees Celsius in its lead shield and used before the labelled expiry, which is a matter of days after calibration.

Mixing

Dispensed patient-by-patient by a radiopharmacy against a scheduled appointment. There is no compounding step at the point of care.

Side effects

  • very commonFatigue— The most consistently reported effect, affecting roughly half of patients.
  • very commonDry mouth (xerostomia)— Salivary glands express PSMA and take up the tracer. Often partly permanent, and the main quality-of-life complaint.
  • very commonNausea— Usually manageable with standard antiemetics.
  • very commonAnaemia— Compounded by extensive bone-marrow metastatic disease in this population.
  • commonThrombocytopenia and neutropenia— Grade 3 or higher in roughly 8 to 10 percent; counts are checked before each cycle.
  • commonConstipation and decreased appetite
  • uncommonRenal impairment— The kidney is a route of clearance and a site of real PSMA expression, so function is tracked throughout.
  • rareSecondary myelodysplastic syndrome— A recognised late risk of any systemic radioligand therapy.

Do not use if

  • Pregnancy and fathering a child — patients must use contraception for at least 14 weeks after the last dose.
  • PSMA-negative disease on PET — without target expression the drug does nothing and the toxicity is unearned.
  • Severe marrow failure or platelets persistently below about 100,000 per microlitre.
  • Urinary incontinence severe enough to make radiation-safety containment impossible during the first days after dosing.

Combining it

  • synergyga-68-psma-11 — PSMA PET is the mandatory companion diagnostic — Locametz and Illuccix exist specifically to select patients for this drug.
  • synergypiflufolastat-f-18 — An alternative PSMA PET tracer with wider availability, used for the same selection purpose.
  • cautionAndrogen receptor pathway inhibitors — Both the 2022 and the 2025 labels are defined by prior ARPI exposure; sequencing decisions belong with the treating oncologist, not with the patient.

What to monitor

  • · PSMA PET before treatment to confirm target expression and rule out significant PSMA-negative disease.
  • · Full blood count before each cycle.
  • · Renal function and liver function before each cycle.
  • · PSA every cycle, interpreted with care because early rises can be flare rather than failure.
  • · Salivary function and dry-mouth symptoms, which drive most quality-of-life complaints.

Legal status

FDA approved in 2022 and expanded in March 2025 to pre-taxane use; also approved in the EU. Administered only in licensed radiopharmaceutical centres.

References

  • Sartor et al. 2021, VISION phase 3 trial of 177Lu-PSMA-617, New England Journal of Medicine (trial)
  • Morris et al. 2024, PSMAfore phase 3 trial in taxane-naive mCRPC, The Lancet (trial)
  • FDA prescribing information for Pluvicto (label)

Mechanism in depth

PSMA, gene name FOLH1, is a type II transmembrane zinc metallopeptidase — a glutamate carboxypeptidase whose ordinary job in the gut is cleaving folate polyglutamates and in the brain is hydrolysing N-acetyl-aspartyl-glutamate. The glutamate-urea-lysine warhead is a transition-state mimic that sits in the active site with the urea carbonyl coordinating the two active-site zinc ions. That is a genuinely different mechanism from the somatostatin drug: this is enzyme inhibition, not receptor agonism, and there is no G protein and no arrestin in the story. Internalisation still happens, driven by the constitutive clathrin-dependent recycling that PSMA runs anyway through its N-terminal internalisation motif, and the radioligand is dragged along and stranded in endosomes. That constitutive internalisation is why PSMA is such an unusually good target: expression runs 100 to 1000-fold higher in metastatic prostate cancer than in normal prostate, and it tends to rise rather than fall under androgen deprivation, so the target is enriched in exactly the population being treated. The signature toxicity follows straight from physiology. Salivary and lacrimal glands express real PSMA, take up real drug and receive real radiation, so xerostomia is on-target toxicity that no dose refinement fully removes. The kidney takes up drug both through proximal tubular PSMA expression and through filtration. Small bowel expresses it in the brush border. None of this is off-target in any meaningful sense — the drug is doing exactly what it was built to do, in tissues you wish it would ignore. The last piece is heterogeneity: a meaningful fraction of screened patients are excluded for PSMA-negative lesions, and within a treated patient it is the PSMA-negative clone that comes back.

What usually goes wrong

Dry mouth is the complaint that actually changes lives and it is systematically under-warned. It starts within days of the first cycle, it is on-target, it does not reliably recover, and for some men it is bad enough to affect eating and sleeping permanently. The second common failure is treating on the strength of an imperfect scan: significant PSMA-negative volume, or FDG-avid PSMA-negative disease that was never looked for, means the drug irradiates the compliant tumour while the resistant clone takes over. The third is stopping on a cycle-one PSA rise that was flare. Beyond that, marrow reserve in men with extensive bone metastases and prior chemotherapy is often already spent, so a cycle delay in this population frequently becomes a permanent discontinuation. And as with any systemic radioligand therapy there is a late myelodysplasia risk — rarer than with the somatostatin drug because the courses are shorter and life expectancy is shorter, but not zero.

Bloodwork worth running

MarkerWhenWhy it matters
PSABefore every cycle, so six times across the course.The efficacy readout and the one most likely to be misread. A rise across the first cycle can be flare from tumour lysis rather than failure, and acting on a single early rise is a common way to stop a drug that was working.Act if: A fall of 50 percent or more is the conventional response benchmark. Do not call progression on PSA alone before cycle three — confirm it with imaging.
HaemoglobinBefore each cycle.Anaemia is very common and is compounded by extensive marrow metastatic disease in this population, so it is partly drug and partly the cancer.Act if: Grade 3 anaemia, below 8 g/dL, means hold and transfuse. Recurrent grade 3 drops the activity to 5.5 GBq.
Platelet countBefore each cycle.Grade 3 or higher thrombocytopenia occurred in roughly 8 percent on VISION and is the count that most often forces a cycle delay.Act if: Persistently below 100,000 per microlitre is treatment-limiting. Hold, allow up to a 4-week delay for recovery, then reduce activity.
Absolute neutrophil countBefore each cycle.Less prominent than thrombocytopenia here, but it drives infection risk in men who are frequently also on steroids.Act if: Below 1,000 per microlitre, hold.
Serum creatinine and eGFRBefore each cycle and periodically afterwards.The kidney takes both filtered load and genuine PSMA-mediated uptake. Renal decline is less dramatic than with the somatostatin drug but it is not absent.Act if: A confirmed 40 percent rise in creatinine from baseline, or a 40 percent fall in creatinine clearance, is a dose-modification trigger.
ALT, AST, alkaline phosphatase and bilirubinBefore each cycle.Liver metastases are common in this population, and alkaline phosphatase also tracks bone disease burden and can flare early with response.Act if: Grade 3 hepatotoxicity is a hold-and-reduce trigger.
TestosteroneAt baseline, and any time PSA behaves unexpectedly.Androgen deprivation must continue throughout. If testosterone escapes castrate range the treatment context has changed and PSA becomes uninterpretable.Act if: Above 50 ng/dL means the androgen deprivation has failed and needs fixing before anything is concluded about the radioligand.

Pharmacokinetics

Tmax
0.5 h
Bioavailability
100%
Volume of distribution
123 L
Protein binding
65%
Crosses blood-brain barrier
no
Metabolism
None. The label is explicit that it undergoes neither hepatic nor renal metabolism. The molecule is excreted intact.
Elimination
Primarily renal, as unchanged drug. This is why patients are told to hydrate hard and void frequently for the first 24 hours — unbound tracer sitting in the bladder is pure unnecessary dose to the bladder wall.

Receptor targets

  • Prostate-specific membrane antigen (PSMA / FOLH1 / glutamate carboxypeptidase II) — Low nanomolar. Published inhibition constants for PSMA-617 sit in the single-digit nanomolar range but vary substantially with assay format.

    Active-site occupancy followed by constitutive receptor-mediated internalisation and endosomal retention of lutetium-177, delivering a cell-autonomous beta dose over days.

  • PSMA in salivary and lacrimal gland — Identical molecular target at physiological expression levels

    Genuine on-target uptake producing xerostomia and dry eye. This is the main quality-of-life cost of the drug and it is often partially permanent.

  • PSMA in renal proximal tubule and small bowel brush border — Identical molecular target at physiological expression levels

    Adds to renal dose on top of filtration, and contributes to the nausea and appetite loss.

  • Tumour cell nuclear DNA

    Beta-minus double-strand breaks with a mean tissue range under a millimetre. The short range is why a PSMA-negative deposit sitting beside a PSMA-avid one survives.

Trials

  • VISION Phase 3 · n=831 · 36 weeks · 2021

    Alternate primary endpoints of overall survival and radiographic progression-free survival. Median overall survival 15.3 versus 11.3 months, hazard ratio 0.62. Median radiographic PFS 8.7 versus 3.4 months, hazard ratio 0.40. Population was heavily pretreated metastatic castration-resistant prostate cancer after an androgen receptor pathway inhibitor and one or two taxanes.

  • PSMAfore Phase 3 · n=468 · 2024

    Radiographic progression-free survival in taxane-naive patients versus a change of androgen receptor pathway inhibitor. Median rPFS 12.02 versus 5.59 months, hazard ratio 0.41. This is the trial behind the March 2025 pre-chemotherapy label expansion.

What to expect, and when

PSA usually starts moving after the first or second cycle, so 6 to 12 weeks. Pain relief in bone-dominant disease often arrives before any PSA change, sometimes within two to three weeks of the first dose. Dry mouth appears within the first week or two and worsens cumulatively across cycles. Fatigue peaks in the week after each infusion. Radiographic response lags PSA by roughly two to three months. Counts drift down across the six cycles rather than nadiring sharply, so the count at cycle five is what decides whether cycle six happens.

Stacking and comparisons

Androgen deprivation continues throughout — this is added to castration, never substituted for it. Bone-protective therapy with denosumab or zoledronic acid also continues and there is no interaction to manage. The mandatory partner is the PSMA PET, and the mandate is real: patients with PSMA-negative lesions on screening were excluded from VISION and would get toxicity without benefit. Hydration before and after is not a formality; it clears unbound tracer from the bladder and cuts bladder wall dose. Salivary protection has been tried with ice packs, sour sweets and cholinergic agents, and none of it has convincing evidence — the cooling trials were negative or equivocal. Sequencing against taxanes is a live question after the 2025 label expansion and the honest answer is that the optimal order is unsettled. What to avoid: another myelosuppressive agent alongside it, and a second radiopharmaceutical such as radium-223 without a long gap, because it is cumulative marrow dose that generates the myelodysplasia risk.

Against lutetium Lu-177 dotatate the isotope is identical and the dosimetry broadly similar, but the dose-limiting organ moves from kidney to salivary gland, the mechanism moves from receptor agonism to enzyme active-site inhibition, and there is no protective amino acid infusion because the renal handling is different. Against radium-223, an alpha emitter for bone-only disease, this treats soft tissue and nodal disease as well and has a survival benefit in a broader population, while radium-223 has a much gentler marrow profile. Against a taxane in the same line, the PSMAfore progression-free survival advantage is real but the survival comparison was undermined by crossover, so anyone claiming it definitively beats chemotherapy on survival is over-reading the data. Against actinium-225 PSMA-617, early series show responses in lutetium-refractory disease at the cost of far worse xerostomia — severe enough that some patients stop for that reason alone.

Rough cost

Not characterised here. As with the somatostatin radioligand, this is a per-dose radiopharmacy charge negotiated between institution and payer, with the PSMA PET, the infusion suite and the ongoing androgen deprivation billed separately. Any single monthly figure would be invented.

Genuinely uncertain

  • PSMA-617 binding affinity is given as a range. Reported inhibition constants differ by assay and I did not resolve a primary source in this session.
  • Molecular weight is left null as in the Core record, because the compound is defined by its radiolabelled form and quoted masses in secondary sources are inconsistent about whether lutetium and counterions are included.
  • The 36-week VISION duration is the maximum six cycles at six-week intervals, not a reported trial parameter.
  • The claim that PSMA expression rises under androgen deprivation is directionally well supported but the magnitude and timing are inconsistent across studies, which matters for scan timing and is unsettled.
  • Whether salivary protection measures work is genuinely unresolved; the small trials of cooling and sialogogues have been negative or equivocal.
  • The exact proportion of screened patients excluded for PSMA-negative disease varies by centre and reading criteria; I have avoided quoting a precise figure.
  • Protein binding is entered as 65 percent, the midpoint of the label's stated 60 to 70 percent range, because the schema takes a single number.

Papers